These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25815155)

  • 1. Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.
    Rouquet G; Moore DE; Spain M; Allwood DM; Battilocchio C; Blakemore DC; Fish PV; Jenkinson S; Jessiman AS; Ley SV; McMurray G; Storer RI
    ACS Med Chem Lett; 2015 Mar; 6(3):329-33. PubMed ID: 25815155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective 5-HT2C receptor agonists: Design and synthesis of pyridazine-fused azepines.
    Green MP; McMurray G; Storer RI
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4117-21. PubMed ID: 27381086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.
    Brennan PE; Whitlock GA; Ho DK; Conlon K; McMurray G
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4999-5003. PubMed ID: 19646865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT
    Schrader TO; Kasem M; Ren A; Feichtinger K; Al Doori B; Wei J; Wu C; Dang H; Le M; Gatlin J; Chase K; Dong J; Whelan KT; Sage C; Grottick AJ; Semple G
    Bioorg Med Chem Lett; 2016 Dec; 26(24):5877-5882. PubMed ID: 27864071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Biological Evaluation of Disubstituted Pyrimidines as Selective 5-HT
    Kim J; Kim YJ; Londhe AM; Pae AN; Choo H; Kim HJ; Min SJ
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31491978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT
    Carpenter J; Wang Y; Wu G; Feng J; Ye XY; Morales CL; Broekema M; Rossi KA; Miller KJ; Murphy BJ; Wu G; Malmstrom SE; Azzara AV; Sher PM; Fevig JM; Alt A; Bertekap RL; Cullen MJ; Harper TM; Foster K; Luk E; Xiang Q; Grubb MF; Robl JA; Wacker DA
    J Med Chem; 2017 Jul; 60(14):6166-6190. PubMed ID: 28635286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
    Cussac D; Boutet-Robinet E; Ailhaud MC; Newman-Tancredi A; Martel JC; Danty N; Rauly-Lestienne I
    Eur J Pharmacol; 2008 Oct; 594(1-3):32-8. PubMed ID: 18703043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
    Cussac D; Newman-Tancredi A; Quentric Y; Carpentier N; Poissonnet G; Parmentier JG; Goldstein S; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Mar; 365(3):242-52. PubMed ID: 11882920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.
    Porter RH; Benwell KR; Lamb H; Malcolm CS; Allen NH; Revell DF; Adams DR; Sheardown MJ
    Br J Pharmacol; 1999 Sep; 128(1):13-20. PubMed ID: 10498829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
    Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.
    Kennett GA; Wood MD; Bright F; Cilia J; Piper DC; Gager T; Thomas D; Baxter GS; Forbes IT; Ham P; Blackburn TP
    Br J Pharmacol; 1996 Feb; 117(3):427-434. PubMed ID: 8821530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of homogeneous high-affinity agonist binding assays for 5-HT2 receptor subtypes.
    Song J; Hanniford D; Doucette C; Graham E; Poole MF; Ting A; Sherf B; Harrington J; Brunden K; Stricker-Krongrad A
    Assay Drug Dev Technol; 2005 Dec; 3(6):649-59. PubMed ID: 16438660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement.
    Duxon MS; Stretton J; Starr K; Jones DN; Holland V; Riley G; Jerman J; Brough S; Smart D; Johns A; Chan W; Porter RA; Upton N
    Psychopharmacology (Berl); 2001 Jan; 153(2):203-9. PubMed ID: 11205420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.
    Cheng J; Giguère PM; Onajole OK; Lv W; Gaisin A; Gunosewoyo H; Schmerberg CM; Pogorelov VM; Rodriguiz RM; Vistoli G; Wetsel WC; Roth BL; Kozikowski AP
    J Med Chem; 2015 Feb; 58(4):1992-2002. PubMed ID: 25633969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Discovery of Functionally Selective Serotonin 2C (5-HT
    Cheng J; McCorvy JD; Giguere PM; Zhu H; Kenakin T; Roth BL; Kozikowski AP
    J Med Chem; 2016 Nov; 59(21):9866-9880. PubMed ID: 27726356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.
    Nirogi R; Mohammed AR; Shinde AK; Bogaraju N; Gagginapalli SR; Ravella SR; Kota L; Bhyrapuneni G; Muddana NR; Benade V; Palacharla RC; Jayarajan P; Subramanian R; Goyal VK
    Eur J Med Chem; 2015 Oct; 103():289-301. PubMed ID: 26363507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.
    Zhao G; Kwon C; Bisaha SN; Stein PD; Rossi KA; Cao X; Ung T; Wu G; Hung CP; Malmstrom SE; Zhang G; Qu Q; Gan J; Keim WJ; Cullen MJ; Rohrbach KW; Devenny J; Pelleymounter MA; Miller KJ; Robl JA
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3914-9. PubMed ID: 23683593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT2C receptors mediate penile erections in rats: actions of novel and selective agonists and antagonists.
    Millan MJ; Peglion JL; Lavielle G; Perrin-Monneyron S
    Eur J Pharmacol; 1997 Apr; 325(1):9-12. PubMed ID: 9151932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of novel hexahydro-pyrido[3',2':4,5]pyrrolo[1,2-a]pyrazines as potent and selective 5-HT(2C) receptor agonists.
    Richter HG; Adams DR; Benardeau A; Bickerdike MJ; Bentley JM; Blench TJ; Cliffe IA; Dourish C; Hebeisen P; Kennett GA; Knight AR; Malcolm CS; Mattei P; Misra A; Mizrahi J; Monck NJ; Plancher JM; Roever S; Roffey JR; Taylor S; Vickers SP
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1207-11. PubMed ID: 16361098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity.
    Forbes IT; Ham P; Booth DH; Martin RT; Thompson M; Baxter GS; Blackburn TP; Glen A; Kennett GA; Wood MD
    J Med Chem; 1995 Jul; 38(14):2524-30. PubMed ID: 7629791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.